Literature DB >> 23867877

Reversible retinopathy associated with oral deferasirox therapy.

Harpreet S Walia1, Jiong Yan.   

Abstract

A 17-year-old girl with a history of sickle cell anaemia undergoing chronic blood transfusions and iron-chelation therapy presented for multiple ophthalmic examinations. During treatment with deferoxamine, her examination remained stable but 2 years after changing to deferasirox she presented with decreased visual acuity and only mild funduscopic changes. Marked electrophysiological abnormalities were also evident. After cessation of deferasirox, her visual acuity improved and electrophysiological responses improved. No prior reports of deferasirox-related retinopathy are available. We suggest that oral deferasirox caused a reversible retinopathy in our patient and clinicians be aware of this entity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23867877      PMCID: PMC3736105          DOI: 10.1136/bcr-2013-009205

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

1.  Effects of desferoxamine on retinal and visual function.

Authors:  Ming Lu; Ronald M Hansen; Melody J Cunningham; Susan E Eklund; Anne B Fulton
Journal:  Arch Ophthalmol       Date:  2007-11

2.  Turning a blind eye to deferasirox's toxicity?

Authors:  G J Kontoghiorghes
Journal:  Lancet       Date:  2013-04-06       Impact factor: 79.321

3.  Ocular toxicity of desferrioxamine--an example of copper promoted auto-oxidative damage?

Authors:  H Pall; D R Blake; P Winyard; J Lunec; A Williams; P A Good; E E Kritzinger; A Cornish; R C Hider
Journal:  Br J Ophthalmol       Date:  1989-01       Impact factor: 4.638

Review 4.  Iron-chelating therapy for transfusional iron overload.

Authors:  Gary M Brittenham
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

5.  The expanded clinical spectrum of deferoxamine retinopathy.

Authors:  Robert Haimovici; Donald J D'Amico; Evangelos S Gragoudas; Samuel Sokol
Journal:  Ophthalmology       Date:  2002-01       Impact factor: 12.079

Review 6.  Long-term efficacy and safety of deferasirox.

Authors:  Maria Domenica Cappellini
Journal:  Blood Rev       Date:  2008-12       Impact factor: 8.250

7.  Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population.

Authors:  Jasrajbir S Baath; Wai-Ching Lam; Melanie Kirby; Anne Chun
Journal:  Retina       Date:  2008-06       Impact factor: 4.256

  7 in total
  6 in total

1.  BULL'S EYE MACULOPATHY POSSIBLY DUE TO IRON OVERLOAD IN A CHILD WITH THALASSEMIA MAJOR: A CASE OF POSSIBLE "FERRITIN RETINOPATHY".

Authors:  Anina Abraham
Journal:  Retin Cases Brief Rep       Date:  2021-07-01

Review 2.  Sickle cell retinopathy: improving care with a multidisciplinary approach.

Authors:  Farid Menaa; Barkat Ali Khan; Bushra Uzair; Abder Menaa
Journal:  J Multidiscip Healthc       Date:  2017-08-30

3.  A Case of Angioid Streaks in Congenital Dyserythropoietic Anaemia Type II.

Authors:  Emer Doolan; Andrea Ryan
Journal:  Case Rep Ophthalmol       Date:  2022-01-11

4.  Iron overload and iron chelating agent exposure in anemia-associated outer retinal degeneration: a case report and review of the literature.

Authors:  Mohamed Belmouhand; Christina Eckmann-Hansen; Tomas Ilginis; Eva Birgitte Leinøe; Bo Kok Mortensen; Michael Larsen
Journal:  BMC Ophthalmol       Date:  2021-07-13       Impact factor: 2.209

5.  Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature.

Authors:  Constantine D Georgakopoulos; Foteini Tsapardoni; Elli V Kostopoulou; Olga E Makri
Journal:  BMC Ophthalmol       Date:  2018-09-12       Impact factor: 2.209

Review 6.  [Maculopathy in sickle cell disease].

Authors:  Isabel Bachmeier; Christiane Blecha; Jürgen Föll; Daniel Wolff; Herbert Jägle
Journal:  Ophthalmologe       Date:  2021-01-27       Impact factor: 1.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.